Study shows efficacy of AT-01 amyloid imaging agent

2021-06-17

Research presented at the SNMMI Virtual Annual Meeting showed Attralus' AT-01 amyloid imaging agent, which is under evaluation in a Phase 1/2 clinical trial in patients with systemic amyloidosis, helped detect seven types of amyloid on PET/CT imaging. Attralus said its imaging agent also detected amyloid, including presymptomatic cardiac amyloid, in anatomic sites not detected clinically.

Full story:

SNMMI SmartBrief

Nuclear medicine, molecular imaging and therapy

Designed specifically for nuclear medicine and molecular imaging professionals, SNMMI SmartBrief is a FREE, daily e-mail newsletter. It provides the latest news and information to save you time and keep you informed on our profession.